NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TVGN

Tevogen Bio Holdings Inc

May 19 • 01:30PM ET

1.13

Dollar change +0.00
Percentage change 0.01	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA CRSP GILD FATE EDIT ALLO IMTX ADAP PSTX BLUE

| Held by: VTI IBB IWO VXF IWN VTWO IWC RSSL VTWG IBBQ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.19	Insider Own	85.39%	Shs Outstand	183.89M	Perf Week	-5.03%
Market Cap	207.82M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-0.42%	Shs Float	26.87M	Perf Month	15.36%
Income	-31.74M	PEG	-	EPS next Q	-0.05	Inst Own	2.09%	Short Float	11.98%	Perf Quarter	-30.67%
Sales	0.00M	P/S	-	EPS this Y	43.59%	Inst Trans	-41.09%	Short Ratio	3.57	Perf Half Y	-37.22%
Book/sh	-0.09	P/B	-	EPS next Y	-4.55%	ROA	-849.23%	Short Interest	3.22M	Perf Year	16.57%
Cash/sh	0.01	P/C	105.49	EPS next 5Y	-	ROE	-124.74%	52W Range	0.26 - 3.09	Perf YTD	9.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-63.43%	Beta	-0.75
Dividend TTM	-	Quick Ratio	0.35	Sales past 5Y	0.00%	Gross Margin	-	52W Low	342.14%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.35	EPS Y/Y TTM	-2048.31%	Oper. Margin	-	RSI (14)	54.63	Volatility	6.79% 7.68%
Employees	18	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	74.98%	Payout	-	Rel Volume	0.34	Prev Close	1.13
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Apr 30	Avg Volume	900.37K	Price	1.13
SMA20	6.88%	SMA50	4.76%	SMA200	2.89%	Trades		Volume	192,363	Change	0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Initiated	D. Boral Capital	Buy	$10

May-12-25 08:00AM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +9.17%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
May-02-25 03:45PM	Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.01%
Apr-30-25 03:49PM	CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment (GlobeNewswire)
04:50PM	Loading…
Apr-29-25 04:50PM	Tevogen sees launch year oncology business revenue $1B (TipRanks) +7.74%
01:48PM	Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts (GlobeNewswire)
08:00AM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-28-25 04:36PM	Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion (GlobeNewswire) -5.52%
Apr-25-25 02:33PM	Tevogen Bio Announces 2025 Annual Meeting (GlobeNewswire)
Apr-17-25 02:54PM	Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility (GlobeNewswire)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Apr-15-25 02:03PM	Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction (GlobeNewswire)
Apr-14-25 01:53PM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-11-25 04:00PM	Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints (Seeking Alpha) +8.00%
02:45PM	Loading…
Apr-09-25 02:45PM	Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States (GlobeNewswire) +16.67%
Apr-08-25 05:53PM	Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs (GlobeNewswire) -6.80%
Apr-07-25 03:58PM	Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission (GlobeNewswire)
Mar-26-25 03:12PM	Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast (GlobeNewswire)
Mar-25-25 01:11PM	Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan (GlobeNewswire)
Mar-10-25 12:40PM	Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO (GlobeNewswire) -7.02%
Mar-07-25 04:09PM	Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel (GlobeNewswire)
Mar-03-25 12:52PM	Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations (GlobeNewswire) -7.81%
Feb-28-25 01:17PM	Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy (GlobeNewswire)
Feb-21-25 03:28PM	Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned (GlobeNewswire) -8.71%
Feb-14-25 06:31PM	Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision (GlobeNewswire)
01:16PM	Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency (GlobeNewswire)
11:52AM	Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity (GlobeNewswire)
Feb-13-25 04:34PM	Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans (GlobeNewswire) -6.02%
Feb-10-25 05:30PM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +5.44%
02:56PM	Loading…
Feb-07-25 02:56PM	Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell Technology's Potential as a Scalable Medical Countermeasure (GlobeNewswire)
Jan-29-25 02:33PM	Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration (Insider Monkey) -5.23%
Jan-28-25 03:49PM	Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding (GlobeNewswire) -8.93%
Jan-27-25 02:24PM	Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach (GlobeNewswire) +24.44%
Jan-24-25 05:34PM	Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure (GlobeNewswire)
Jan-23-25 07:53PM	Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 12:21PM	Tevogen Bio to Host Panel Discussions AI In Biopharma: Next Frontier of Medical Innovation and Pioneering the Economics of Health: Balancing Access and Outcomes During J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-24 09:38AM	Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:30AM	Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda (GlobeNewswire) +12.14%
Dec-17-24 01:32PM	Tevogen Bio to Host Panel Pioneering the Economics of Health: Balancing Access and Outcomes During the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.88%
Dec-10-24 03:13PM	Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.77%
Dec-05-24 11:03AM	Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame (GlobeNewswire) -7.08%
Nov-26-24 08:05AM	Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy (GlobeNewswire) -5.63%
Nov-21-24 03:59PM	Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value (GlobeNewswire) +15.49%
Nov-19-24 04:50PM	Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model (GlobeNewswire)
Nov-14-24 05:00PM	UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials (GlobeNewswire) -17.78%
03:49PM	Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials (GlobeNewswire)
Nov-08-24 03:36PM	Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations (GlobeNewswire) +7.02%
Nov-05-24 04:43PM	Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability (GlobeNewswire) -12.24% -24.42%
09:27AM	Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 (GlobeNewswire)
Nov-04-24 02:36PM	Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support (GlobeNewswire) -17.30%
Oct-31-24 10:54AM	Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs (GlobeNewswire)
Oct-29-24 03:28PM	Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company (GlobeNewswire) -6.93%
02:38PM	Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million (GlobeNewswire)
12:43PM	Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity (GlobeNewswire)
Oct-25-24 05:34PM	Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas (GlobeNewswire) +19.14% -10.16%
Oct-23-24 08:35AM	Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development (GlobeNewswire) +54.04%
Oct-22-24 02:30PM	Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week (GlobeNewswire) -10.56%
Oct-21-24 03:58PM	Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion (GlobeNewswire)
01:56PM	Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days (GlobeNewswire)
Oct-18-24 10:46PM	Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days (GlobeNewswire) +24.64%
Oct-17-24 09:32AM	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire) +32.69%
07:54AM	Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion (GlobeNewswire)
Oct-16-24 04:30PM	Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality (GlobeNewswire) -24.09%
Oct-15-24 02:30PM	Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions (GlobeNewswire) +25.69%
11:36AM	Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use (GlobeNewswire)
Oct-14-24 06:43PM	Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections (GlobeNewswire) +187.14%
11:39AM	Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio (News Direct)
Oct-11-24 03:59PM	Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 (GlobeNewswire) +18.51%
12:12PM	Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID (GlobeNewswire)
Oct-08-24 02:40PM	Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation (GlobeNewswire)
Sep-24-24 11:09AM	Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation (GlobeNewswire)
Aug-22-24 09:00AM	Tevogen Bio Secures $6 Million Series C Preferred Stock Investment (GlobeNewswire)
Aug-15-24 12:17PM	CORRECTION - Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares (GlobeNewswire)
09:00AM	Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares (GlobeNewswire)
Aug-14-24 09:00AM	Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health (GlobeNewswire) +6.63%
Aug-09-24 11:00AM	Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities (GlobeNewswire)
Jul-11-24 12:21PM	Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback (GlobeNewswire)
Jul-10-24 08:05AM	Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian (GlobeNewswire)
Jul-08-24 04:07PM	Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility (GlobeNewswire)
Jun-26-24 12:46PM	Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities (GlobeNewswire) +7.45%
Jun-25-24 08:05AM	Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances (GlobeNewswire) -10.35%
Jun-18-24 03:17PM	Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference (GlobeNewswire) -8.31%
Jun-12-24 03:45PM	Tevogen Bio Set to Join Russell 3000 Index (GlobeNewswire)
Jun-11-24 03:30PM	Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts (GlobeNewswire) +6.50%
Jun-07-24 03:32PM	CORRECTION Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event (GlobeNewswire) -7.23%
Jun-06-24 06:14PM	Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event (GlobeNewswire) +14.90%
03:52PM	Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 (GlobeNewswire)
May-30-24 06:52PM	TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024 (InvestorPlace)
May-29-24 08:00AM	Tevogen Bio Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 02:00PM	Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives (GlobeNewswire) -8.20%
May-13-24 07:52AM	Why Is Tevogen Bio (TVGN) Stock Up 54% Today? (InvestorPlace)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-10-24 05:40PM	Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives (GlobeNewswire)
May-01-24 08:05AM	Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives (GlobeNewswire)
Apr-26-24 09:23AM	Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments (GlobeNewswire) +17.65%
Apr-11-24 08:05AM	Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers (GlobeNewswire)
Apr-03-24 08:05AM	Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development (GlobeNewswire) -11.19%
Mar-28-24 08:05AM	Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price (GlobeNewswire) +8.05%
Mar-27-24 09:20AM	Tevogen Bio Announces Series A-1 Preferred Stock Investment (GlobeNewswire) -10.65%

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flomenberg Neal	See Remarks	Mar 12 '25	Sale	1.09	232,968	253,935	3,595,608	Mar 14 09:02 PM
Flomenberg Neal	See Remarks	Mar 07 '25	Sale	1.14	71,273	81,251	3,969,212	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 10 '25	Sale	1.09	70,384	76,719	3,898,828	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 11 '25	Sale	1.05	70,252	73,765	3,828,576	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 05 '25	Sale	1.21	110,659	133,897	4,129,004	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Mar 06 '25	Sale	1.10	88,519	97,371	4,040,485	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Mar 04 '25	Sale	1.28	14,639	18,738	4,239,663	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Oct 17 '24	Sale	1.62	1,078,600	1,747,332	4,254,302	Oct 18 09:57 PM
Desai Kirti	Chief Financial Officer	Jun 12 '24	Buy	0.82	3,000	2,460	9,699,186	Jun 13 04:30 PM
Saadi Ryan H.	Chief Executive Officer	Jun 05 '24	Buy	0.77	2,607	2,000	118,252,659	Jun 07 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc

Upgrade your FINVIZ experience